Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study - American Journal of Transplantation
Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients - Hartinger - 2022 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions - ScienceDirect
Enhanced Humoral Immune Response After COVID-19 Vaccination... : Transplantation
Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Everolimus dose and trough blood levels, and laboratory values for... | Download Scientific Diagram
An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients - ScienceDirect
PDF) Conversion to everolimus in maintenance patients - Current clinical strategies
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies - ATC Abstracts
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de
Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients | PLOS ONE
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study - ATC Abstracts
IJMS | Free Full-Text | Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
De Novo Therapy with Everolimus and Low-Dose Calcineurin Inhibitors in Kidney Transplantation | Semantic Scholar
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil | PLOS ONE
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
Full article: The use of everolimus in renal-transplant patients
Everolimus Dosage Guide + Max Dose, Adjustments - Drugs.com
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study - ATC Abstracts
Study design. Steroid dose will be at least 5 mg prednisolone or... | Download Scientific Diagram
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial - The Lancet
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Transplantology | Free Full-Text | Dyslipidemia in Renal Transplant Recipients
